Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Treatment of the neuro-ophthalmologic sequelae of MS (such as oscillopsia from nystagmus or vision loss from optic neuritis) is anchored in treatment of the underlying disease, and supplemented by ...

RCOphth Eponymous Lectures Published: 01 April 2005 The Bowman Lecture 2004 Optic nerve axons: life and death before birth D Taylor Eye 19, 499–527 (2005) Cite this article ...

While ketogenic diets have been proposed to offer anti-inflammatory benefits in MS, the findings suggest the type of fat may ...

Acute demyelinating optic neuritis (referred to herein as optic neuritis) is one of the most common manifestations of MS and often occurs as a first demyelinating event. Patients present with loss ...

Aim: To establish the clinical profile of simultaneous bilateral optic neuritis in adults, the efficacy of steroid therapy, extent of visual recovery, and neurological outcome. Methods: The authors ...

Aim To quantify structural and functional degeneration in the retinal nerve fibre layer (RNFL) of patients with multiple sclerosis (MS) over a 2-year time period, and to analyse the effect of prior ...

In 2024, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress celebrated a remarkable 40 years of pioneering work. Regional committees have emerged around the ...

Ms. Rachel, the wildly successful children’s entertainer, has become one of Hollywood’s most outspoken advocates for children in critical conflict zones like Gaza. All the work Ms. Rachel is ...

Objective: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study. Methods: In total, 630 ...

We had no idea what this condition was, and what this meant for our baby girl." Optic nerve hypoplasia is a congenital disorder where the optic nerves in the eye are underdeveloped.

A study of people with diabetes found the risk of macular degeneration remained low, but was 0.2% in people taking GLP-1s, 0.1% in those who didn't.